Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Illumina Inc - SIC # 3826 - LABORATORY ANALYTICAL INSTRUMENTS
Ticker
Exchange
SIC #
Website
Latest Ticker
ILMN
Nasdaq
3826
https://www.illumina.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Illumina Inc
Illumina (NASDAQ:ILMN) investors are sitting on a loss of 71% if they invested three years ago
- Apr 23rd, 2024 11:38 am
This CEO has battled billionaire activist Carl Icahn twice — here's his advice to Disney CEO Bob Iger
- Apr 21st, 2024 12:30 pm
20 Countries with the Highest Cancer Survival Rates in the World
- Apr 19th, 2024 6:05 pm
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
- Apr 19th, 2024 4:10 pm
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Apr 19th, 2024 1:00 pm
Engineering a Cool Career in Biotech - and Volunteering Along the Way
- Apr 18th, 2024 5:30 pm
QQQ Has Some Inexpensive Growth Stocks
- Apr 18th, 2024 12:00 pm
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic
- Apr 17th, 2024 1:30 pm
European Commission approves Illumina’s proposed Grail split
- Apr 15th, 2024 9:40 am
Illumina's planned divestment of GRAIL approved by the European Commission
- Apr 12th, 2024 1:00 pm
UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail
- Apr 12th, 2024 10:21 am
EU approves Illumina's plan to divest cancer test maker Grail
- Apr 12th, 2024 9:49 am
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure
- Apr 10th, 2024 12:16 pm
Illumina CFO steps down amid executive shakeup
- Apr 10th, 2024 3:37 am
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
- Apr 9th, 2024 9:28 pm
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
- Apr 9th, 2024 8:32 pm
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
- Apr 9th, 2024 8:05 pm
Nasdaq’s Nosebleed Section: 3 Expensive Stocks to Sell Before It’s Too Late
- Apr 5th, 2024 6:27 pm
Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer
- Apr 5th, 2024 4:45 pm
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
- Apr 4th, 2024 9:00 pm
Scroll